Nuevocor is a Singapore-based biotech firm has achieved a significant milestone by securing a substantial $45 million Series B funding round. This considerable investment is poised to catapult the development of its gene therapies particularly those targeting genetic cardiomyopathies and heart conditions that currently lack effective treatment options into a new phase of advancement.
Innovative Approach to Heart Disease
Nuevocor is pioneering a novel approach to treating genetic cardiomyopathies, focusing on mechanobiology. Its flagship treatment, NVC-001, is a gene therapy designed for patients with lamin A/C (LMNA)-related dilated cardiomyopathy a severe heart condition resulting from mutations in the LMNA gene. This condition, which affects approximately 60,000 individuals in the U.S. and EU, often leads to heart failure and the need for a transplant. Nuevocor’s revolutionary therapy targets the underlying mechanical defects in heart cells offering the potential for a functional cure for those afflicted with this condition.
Innovative Approach to Heart Disease
Nuevocor uses a new science-based approach called mechanobiology to help treat inherited heart diseases. Its main project, NVC-001, is a gene therapy for people with a serious condition called LMNA-related dilated cardiomyopathy. Changes in the LMNA gene cause this condition, affecting about 60,000 people in the U.S. and Europe. It often leads to heart failure and may require a heart transplant. Nuevocor’s therapy is designed to fix the mechanical problems in heart cells hoping to offer a long-term solution or even a cure.
Recognition in the Biotech Community
Nuevocor’s innovative approach has not gone unnoticed in the industry. In September 2024, the company was honored with the prestigious ‘Most Promising Gene Therapy Pipeline in APAC’ award at the Asia Pacific Cell & Gene Therapy Excellence Awards. This recognition underscores Nuevocor’s strong potential to revolutionize the treatment of genetic heart diseases instilling pride and reassurance in our stakeholders.
Looking Ahead
With the new funding and strong leadership, Nuevocor is poised to usher in a new era in the biotech industry. As we move our gene therapies into human trials, we aim to create effective treatments for people with inherited heart diseases. Our unique approach and recent recognition in the biotech world demonstrate that Nuevocor has the potential to significantly impact the treatment of heart conditions inspiring hope and optimism in the industry.
About the company
Nuevocor is a biotech company from Singapore working on gene therapies to treat inherited heart diseases, especially those caused by changes in the LMNA gene. These heart problems can lead to heart failure and, right now, don’t have good treatment options.
Nuevocor was started in 2020 and is led by Dr. Yann Chong Tan, who helped start several biotech companies that raised over $400 million and had successful stock market launches together. The company’s science team includes Dr. Colin Stewart and Dr. Brian Burke, well-known researchers from Singapore’s A*STAR. They are experts in how cells work, especially in cell structure and mechanobiology.
